DengiAll: India's Hope in the Fight Against Dengue

DengiAll, an indigenous one-shot dengue vaccine, is undergoing a Phase III clinical trial in India with 70% of participants enrolled. Overseen by the Indian Council of Medical Research, the trial aims to evaluate the vaccine's efficacy against all four dengue virus serotypes. The trial spans 20 sites nationwide.

India's indigenous dengue vaccine, DengiAll, progresses through its Phase III clinical trial, with Minister Prataprao Jadhav announcing 70% participant enrolment completion during a Lok Sabha session.

The Indian Council of Medical Research spearheads this multicentre, randomized, double-blind study, evaluating DengiAll's effectiveness across 20 sites in India. The trial aims to tackle all four dengue virus serotypes, enhancing protective measures.

In 2024, over 5 lakh dengue cases were confirmed in India, highlighting the urgent need for a vaccine. With no current licensed vaccines, DengiAll's success could be pivotal in India's dengue control strategy.